# Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

> **NCT05263050** · PHASE2 · RECRUITING · sponsor: **Fox Chase Cancer Center** · enrollment: 111 (estimated)

## Conditions studied

- Metastatic Renal Cell Carcinoma
- Clear-cell Metastatic Renal Cell Carcinoma
- Neuroendocrine Tumors
- Carcinoid Tumor

## Interventions

- **DRUG:** Cabozantinib
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT05263050
- **Lead sponsor:** Fox Chase Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-01-21
- **Primary completion:** 2026-02
- **Final completion:** 2027-02
- **Target enrollment:** 111 (ESTIMATED)
- **Last updated:** 2025-12-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05263050

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05263050, "Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors". Retrieved via MORVS 2026-10-15 from https://api.morvs.ai/clinical/NCT05263050. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*